Plain-English translation of NCT03983226 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for women whose ovarian cancer has come back after initial treatment. The study compares two groups: one receives surgery to remove the recurrent cancer followed by chemotherapy and a medication called , while the other group receives chemotherapy and without surgery. The goal is to see whether adding surgery improves outcomes for women whose cancers are sensitive to platinum-based chemotherapy drugs.
When ovarian cancer returns after initial treatment, doctors want to know the best way to treat it. This trial is exploring whether combining surgery with this medication offers better results than using medication alone, which could help improve how recurrent ovarian cancer is managed.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will have surgery to remove recurrent cancer, followed by chemotherapy and then take the medication as a maintenance treatment. The other group will receive chemotherapy and the same maintenance medication, but without surgery. You will have regular visits for imaging scans, blood tests, and check-ups to monitor how well the treatment is working and manage any side effects. The trial is being conducted in China and involves 167 total participants.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China